

Kelly-Anne Phillips, Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2621943/publications.pdf>

Version: 2024-02-01

145
papers

11,048
citations

50276

46
h-index

33894

99
g-index

148
all docs

148
docs citations

148
times ranked

13318
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. <i>Journal of the National Cancer Institute</i> , 2022, 114, 540-552.	6.3	7
2	Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100504.	1.7	1
3	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. <i>Cancer Research</i> , 2022, 82, P5-19-03-P5-19-03.	0.9	0
4	Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline <i>BRCA</i> Pathogenic Variants: A Cause for Concern or Potentially Avoidable?. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200325.	1.6	0
5	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). <i>Cancer Prevention Research</i> , 2022, 15, 185-191.	1.5	4
6	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. <i>Breast</i> , 2022, , .	2.2	2
7	Comparing 5-Year and Lifetime Risks of Breast Cancer Using the Prospective Family Study Cohort. <i>Journal of the National Cancer Institute</i> , 2021, 113, 785-791.	6.3	13
8	A case-only study to identify genetic modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
9	Survival from breast cancer in women with a <i>BRCA2</i> mutation by treatment. <i>British Journal of Cancer</i> , 2021, 124, 1524-1532.	6.4	12
10	Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	11
11	Oral contraceptive use and ovarian cancer risk for <i>BRCA1/2</i> mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	1.3	34
12	The value of clinical breast examination in a breast cancer surveillance program for women with germline <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Medical Journal of Australia</i> , 2021, 215, 460-464.	1.7	4
13	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , 2021, 14, 983-994.	1.5	8
14	Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline <i>BRCA1</i> or <i>BRCA2</i> Pathogenic Variants—Caution Needed. <i>JAMA Oncology</i> , 2021, 7, 1401.	7.1	1
15	Underutilisation of breast cancer prevention medication in Australia. <i>Breast</i> , 2021, 60, 35-37.	2.2	1
16	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. <i>Cancer Prevention Research</i> , 2021, 14, 131-144.	1.5	6
17	Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa110.	2.9	4
18	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab090.	2.9	1

#	ARTICLE	IF	CITATIONS
19	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , 2020, 80, 116-125.	0.9	37
20	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz075.	2.9	11
21	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020, 156, 131-139.	1.4	8
22	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
23	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
24	Key steps for effective breast cancer prevention. <i>Nature Reviews Cancer</i> , 2020, 20, 417-436.	28.4	386
25	The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. <i>Human Reproduction</i> , 2020, 35, 1864-1874.	0.9	36
26	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
27	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	2.5	24
28	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	5.0	41
29	Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14098-e14098.	1.6	1
30	Conservative management of reproductive cancers. Ovarian protection during treatment. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019, 55, 49-58.	2.8	10
31	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz066.	2.9	8
32	Unexpected diagnosis of spinal leptomeningeal metastatic disease on MRI myelography. <i>Journal of Clinical Neuroscience</i> , 2019, 66, 259-261.	1.5	0
33	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. <i>Breast Cancer Research</i> , 2019, 21, 52.	5.0	44
34	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. <i>International Journal of Cancer</i> , 2019, 145, 370-379.	5.1	9
35	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology</i> , The, 2019, 20, 504-517.	10.7	116
36	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). <i>Breast Cancer Research</i> , 2019, 21, 128.	5.0	27

#	ARTICLE	IF	CITATIONS
37	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. Journal of the National Cancer Institute, 2019, 111, 210-213.	6.3	70
38	Does stress increase risk of breast cancer? A 15-year prospective study. Psycho-Oncology, 2018, 27, 1908-1914.	2.3	12
39	Maximizing the Clinical Benefit of DPYD Genotyping: Extending the Opportunity of Personalized Management to Family Members Through Cascade Testing. JCO Precision Oncology, 2018, 2, 1-5.	3.0	0
40	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
41	Preventing ovarian failure associated with chemotherapy. Medical Journal of Australia, 2018, 209, 412-416.	1.7	18
42	Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ. British Journal of Cancer, 2018, 119, 36-39.	6.4	13
43	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. JMIR Formative Research, 2018, 2, e24.	1.4	10
44	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genetics in Medicine, 2017, 19, 30-35.	2.4	53
45	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	7.0	99
46	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
47	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
48	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. Journal of Clinical Oncology, 2017, 35, 804-805.	1.6	20
49	Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?. Breast, 2017, 31, 233-240.	2.2	11
50	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
51	Genetic testing in women with breast cancer: implications for treatment. Expert Review of Anticancer Therapy, 2017, 17, 991-1002.	2.4	9
52	Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer. American Journal of Epidemiology, 2017, 185, 487-500.	3.4	5
53	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
54	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. Australian Journal of Primary Health, 2016, 22, 255.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	1.8	21
56	Anti-Müllerian hormone serum concentrations of women with germline <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Reproduction</i> , 2016, 31, 1126-1132.	0.9	84
57	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964.	6.4	38
58	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). <i>International Journal of Epidemiology</i> , 2016, 45, 683-692.	1.9	48
59	Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory. <i>Patient Education and Counseling</i> , 2016, 99, 814-822.	2.2	21
60	Contralateral prophylactic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction. <i>Breast</i> , 2016, 28, 107-120.	2.2	48
61	Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 359-365.	2.5	96
62	Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour. <i>European Journal of Oncology Nursing</i> , 2016, 21, 57-65.	2.1	10
63	iPrevent: a tailored, web-based, decision support tool for breast cancer risk assessment and management. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 171-182.	2.5	33
64	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
65	No clinical utility of <i>KRAS</i> variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
66	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	5.0	26
67	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
68	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	27.0	452
69	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	56
70	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
71	Assessment of variation in immunosuppressive pathway genes reveals <i>TGFBR2</i> to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 18.	5.0	20
72	Clinical management of women at high risk of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 6-13.	2.0	13

#	ARTICLE	IF	CITATIONS
73	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, 156.	5.5	51
74	Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT). , 2015, , .		2
75	Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?. <i>Future Oncology</i> , 2014, 10, 499-502.	2.4	15
76	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014, 5, 4051.	12.8	16
77	Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory. <i>Patient Education and Counseling</i> , 2014, 96, 106-112.	2.2	20
78	Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer. <i>Familial Cancer</i> , 2014, 13, 153-162.	1.9	5
79	Assessing and managing breast cancer risk: Clinicians' current practice and future needs. <i>Breast</i> , 2014, 23, 644-650.	2.2	44
80	Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique. <i>SpringerPlus</i> , 2014, 3, 264.	1.2	3
81	Abortion and breast cancer risk for Australian women. <i>Medical Journal of Australia</i> , 2014, 201, 381-381.	1.7	1
82	Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 887-896.	2.5	33
83	Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2013, 31, 3091-3099.	1.6	148
84	Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. <i>British Journal of Cancer</i> , 2013, 109, 1296-1301.	6.4	44
85	Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer. <i>Familial Cancer</i> , 2013, 12, 101-109.	1.9	10
86	Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cunningham Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3920-3925.	1.6	42
87	Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. <i>Medical Journal of Australia</i> , 2013, 199, 680-683.	1.7	39
88	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. <i>Journal of Clinical Oncology</i> , 2013, 31, e20660-e20660.	1.6	2
89	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. <i>Journal of Clinical Oncology</i> , 2013, 31, 17-17.	1.6	1
90	Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 1053-1061.	6.4	144

#	ARTICLE	IF	CITATIONS
91	Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 19-26.	1.6	134
92	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316.	1.6	162
93	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	2.9	80
94	Medication to prevent breast cancer "too much to swallow?. <i>Medical Journal of Australia</i> , 2011, 195, 646-649.	1.7	4
95	Morphological predictors of <i>BRCA1</i> germline mutations in young women with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 903-909.	6.4	40
96	Adequacy of risk-reducing gynaecologic surgery in <i>BRCA1</i> or <i>BRCA2</i> mutation carriers and other women at high risk of pelvic serous cancer. <i>Familial Cancer</i> , 2011, 10, 505-514.	1.9	6
97	Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 221-226.	2.5	55
98	Prospective study of breast cancer risk for mutation negative women from <i>BRCA1</i> or <i>BRCA2</i> mutation positive families. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 1057-1061.	2.5	17
99	Contralateral risk-reducing mastectomy in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). <i>Breast Cancer Research and Treatment</i> , 2010, 120, 715-723.	2.5	29
100	Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the breast cancer family registry. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 531-542.	2.5	50
101	Predictors of breast cancer screening behavior in women with a strong family history of the disease. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 509-519.	2.5	46
102	Local therapy in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 389-398.	2.5	170
103	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , 2010, 19, 388-395.	2.2	69
104	Socioeconomic status and survival from breast cancer for young, Australian, urban women. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 200-205.	1.8	5
105	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 492-499.	1.6	42
106	Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1792-1797.	2.5	32
107	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 167-176.	2.5	20
108	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. <i>Familial Cancer</i> , 2009, 8, 451-456.	1.9	21

#	ARTICLE	IF	CITATIONS
109	Risk of Dementia in Older Breast Cancer Survivors: A Population-Based Cohort Study of the Association with Adjuvant Chemotherapy. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 403-411.	2.6	61
110	Australian clinicians and chemoprevention for women at high familial risk for breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 9.	1.5	17
111	Management of Women at High Familial Risk of Breast and Ovarian Cancer. , 2009, , 941-967.		2
112	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 247-252.	2.8	37
113	Psychosocial Factors and Survival of Young Women With Breast Cancer: A Population-Based Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4666-4671.	1.6	77
114	Cancer Risk Management Practices of Noncarriers Within <i>BRCA1/2</i> Mutation-Positive Families in the Kathleen Cunningham Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 225-232.	1.6	19
115	Prostate screening uptake in Australian <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Hereditary Cancer in Clinical Practice</i> , 2007, 5, 161.	1.5	3
116	Prognosis of Breast Cancer in Carriers of <i>BRCA1</i> and <i>BRCA2</i> Mutations. <i>New England Journal of Medicine</i> , 2007, 357, 1555-1556.	27.0	79
117	Analysis of cancer risk and <i>BRCA1</i> and <i>BRCA2</i> mutation prevalence in the kConFab familial breast cancer resource. <i>Breast Cancer Research</i> , 2006, 8, R12.	5.0	135
118	Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. <i>European Journal of Cancer</i> , 2006, 42, 621-628.	2.8	43
119	Risk-reducing surgery, screening and chemoprevention practices of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: a prospective cohort study. <i>Clinical Genetics</i> , 2006, 70, 198-206.	2.0	67
120	Screening behavior in women at increased familial risk for breast cancer. <i>Familial Cancer</i> , 2006, 5, 359-368.	1.9	38
121	Loss of Heterozygosity Analysis in Ductal Lavage Samples from <i>BRCA1</i> and <i>BRCA2</i> Carriers: A Cautionary Tale. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1396-1398.	2.5	5
122	A Randomized Controlled Trial of a Decision Aid for Women at Increased Risk of Ovarian Cancer. <i>Medical Decision Making</i> , 2006, 26, 360-372.	2.4	31
123	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006, 15, 443-451.	2.9	138
124	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. <i>Familial Cancer</i> , 2005, 4, 105-113.	1.9	47
125	Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1686-1691.	2.5	290
126	Agreement Between Self-Reported Breast Cancer Treatment and Medical Records in a Population-Based Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2005, 23, 4679-4686.	1.6	99

#	ARTICLE	IF	CITATIONS
127	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology</i> , The, 2005, 6, 581-588.	10.7	59
128	The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. <i>American Journal of Human Genetics</i> , 2005, 77, 1034-1043.	6.2	197
129	The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. <i>Brain and Cognition</i> , 2005, 59, 60-70.	1.8	269
130	Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 699-705.	1.6	63
131	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 417-421.	1.4	23
132	Screening and Diagnosis of Ovarian Cancer – High Risk. , 2004, , 341-354.		2
133	Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. <i>Human Genetics</i> , 2003, 112, 542-551.	3.8	40
134	Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. <i>Clinical Genetics</i> , 2003, 64, 111-121.	2.0	19
135	Adjuvant Breast Cancer Treatment and Cognitive Function: Current Knowledge and Research Directions. <i>Journal of the National Cancer Institute</i> , 2003, 95, 190-197.	6.3	122
136	HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. <i>Cancer</i> , 2002, 95, 2068-2075.	4.1	61
137	An Online Educational Facility for Medical Oncology Trainees: www.vmotg.org . <i>Journal of Clinical Oncology</i> , 2001, 19, 2566-2569.	1.6	3
138	Current perspectives on BRCA1- and BRCA2-associated breast cancers. <i>Internal Medicine Journal</i> , 2001, 31, 349-356.	0.8	12
139	Prevalence of self-reported arm morbidity following treatment for breast cancer in the Australian Breast Cancer Family Study. <i>Breast</i> , 2001, 10, 515-522.	2.2	52
140	Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 2695-2701.	1.6	511
141	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. <i>Clinical Genetics</i> , 2000, 57, 376-383.	2.0	42
142	Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different?. <i>Journal of Clinical Oncology</i> , 1999, 17, 3653-3663.	1.6	92
143	Putting the Risk of Breast Cancer in Perspective. <i>New England Journal of Medicine</i> , 1999, 340, 141-144.	27.0	98
144	Breast carcinoma in carriers of BRCA1 or BRCA2 mutations. <i>Cancer</i> , 1998, 83, 2251-2254.	4.1	9

#	ARTICLE	IF	CITATIONS
145	Chemotherapy for soft tissue sarcomas. Acta Orthopaedica, 1997, 68, 133-138.	1.4	11